Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cumulative exposure to Fludarabine in patients undergoing reduced intensity allogeneic stem cell transplantation in Belgium
2023-503723-26-00Phase 4Authorised
- Sponsor
- Ghent University Hospital
- Start
- Jun 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fludarabine in hematopoietic malignancies, sponsored by Ghent University Hospital. Primary endpoint: Area under the curve (AUC) of F-Ara-A after exposure to fludarabine. Planned start Jun 2024; status: authorised.
02
Drugs
fludarabine
03
Conditions
hematopoietic malignancies
Beyond the preview
Go deeper on 2023-503723-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503723-26-00.